Global Urological Cancer Market- Industry Analysis, Growth, Segmentation, Trends and Forecast 2020-2026

Global Urological Cancer Market is expected to grow at a CAGR of 19.5% during the forecast period. Global Urological Cancer Market is expected to reach US$ 15.66 Bn. by 2026.

Market Overview & Dynamics:

Urologic cancers are caused by abnormal cell growth that occurs in the organs of the urinary tract, and the male reproductive tract. This may affect the tissues in bladder, kidney, prostate, penile and testicular. Most urologic cancers are treated with surgery, although other treatments are available for some conditions. Frequently, cancers in these organs produce symptoms such as pain, a lump, urinary tract infections (UTIs) or blood in the urine. Urological cancers are thought to account for 19.5% of global cancer prevalence.

Presence of hereditary cancer syndromes is the major driving factor

Family history and genetics, obesity, ageing population, increased usage of tobacco, smoking, herbal supplements containing aristolochic acid, contaminated water with arsenic, unhealthy diet, and lack of awareness about the poor genital hygiene are the major key drivers fuelling the market. Other factors such as new product innovation and research and development activities are likely to drive the market. Rising demand for hormonal therapies to treat cancer is also likely to boost the market. The report has profiled nineteen key players in the market from different regions. However, the report has considered all market leaders, followers, and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and the report has come up with recommendations for a future hot spot in the APAC region.

Segment Analysis:

The Global Urological Cancer is segmented on the basis of cancer type, treatment type and end-users.

Based on the cancer type, urological cancer is bifurcated into Prostate, bladder, kidney and testicular cancer. The prostate cancer segment is the most dominating segment due to its rising prevalence in North America. It is common among many men over age 50. Fortunately, most prostate cancer is detected early. On the basis of treatment type, it is divided into chemotherapy, hormonal therapy, and surgery and radiation therapy. The radiation therapy is most commonly used procedure for the treatment of urological cancer. Radiation therapy like CyberKnife is used in place or after the surgery. The CyberKnife — one of the most advanced forms of radiosurgery — is a painless, non-invasive treatment that delivers high doses of precisely targeted radiation to destroy tumors or lesions within the body. It uses a robotic arm to deliver highly focused beams of radiation. Global Urological Cancer Market To know about the Research Methodology :- Request Free Sample Report

Regional Insights:

Global Urological Cancer Market1

North America is expected to hold a dominant share of xx% during forecast period.

Rising prevalence of prostate cancer, which is common amongst men in US, contributes in the market growth. Prostate cancer affects every 1 in 7 men. In year 2020, it was estimated that 191,930 men in the United States will be diagnosed with prostate cancer. Around 60% of cases are diagnosed in men over 65 years of age. Second most prevalent cancer in US is Bladder Cancer. Europe is expected to hold the second largest share due to rising need for surgeries, rise in consumption of alcohol and smoking behaviour, advanced healthcare and rising awareness about urinary diseases. According to NHS, prostate cancer is the most common cancer among men in the U.K., with over 40,000 new cases diagnosed every year.

Asia Pacific is expected to become the fastest growing region during the forecast period at a CAGR of xx%.

Asia Pacific will command the global market owing to the drivers like improved medical infrastructure, increased healthcare expenditure, and medical tourism, presence of large target, increased awareness, and development of innovative and cost-effective solutions, improved standard of living and rise in disposable income. The market is anticipated to experience fast development in demand for treatment of Urological Cancer in emerging countries such as Japan, China, Brazil, India, Indonesia and South Korea over the forecast period. The report also helps in understanding Global Urological Cancer dynamics, structure by analyzing the market segments and project the Global Urological Cancer size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Urological Cancer make the report investor’s guide.

Scope of the report: Inquire before Buying

Global Urological Cancer Market2

By Region:

• North America • Europe • South America • MEA • APAC

Key Players:

• Pfizer Inc. • Novartis International AG • Johnson & Johnson Private Limited • Astellas Pharma Inc • AstraZeneca Plc. • GlaxoSmithKline plc • Sanofi S.A. • Celgene Corporation • Eli Lilly and Company • Bristol-Myers Squibb Company • F. Hoffmann-La Roche AG. • Kyowa Hakko Kirin Co., Ltd. • Boehringer Ingelheim GmbH • Ferring Pharmaceuticals • Dendreon Corporation • Abbott Laboratories • Roche Healthcare • Indevus Pharmaceuticals Inc • Ipsen
1. Global Urological Cancer Market: Research Methodology 2. Global Urological Cancer Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Urological Cancer Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Urological Cancer Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 1.12 COVID-19 Impact 4. Global Urological Cancer Market Segmentation 4.1 Global Urological Cancer Market, by Cancer Type (2020-2026) • Bladder cancer • Prostate cancer • Testicular cancer • Kidney cancer 4.2 Global Urological Cancer Market, by Treatment Type (2020-2026) • Chemotherapy • Hormonal therapy • Surgery • Radiation therapy 4.3 Global Urological Cancer Market, by End-Users (2020-2026) • Hospitals • Urological centers • Oncology centers • Specialty clinics 5. North America Urological Cancer Market (2020-2026) 5.1 Global Urological Cancer Market, by Cancer Type (2020-2026) • Bladder cancer • Prostate cancer • Testicular cancer • Kidney cancer 5.2 Global Urological Cancer Market, by Treatment Type (2020-2026) • Chemotherapy • Hormonal therapy • Surgery • Radiation therapy 5.3 Global Urological Cancer Market, by End-Users (2020-2026) • Hospitals • Urological centers • Oncology centers • Specialty clinics 5.4 North America Urological Cancer Market, by Country (2020-2026) • United States • Canada • Mexico 6. Asia Pacific Urological Cancer Market (2020-2026) 6.1. Asia Pacific Urological Cancer Market, by Cancer Type (2020-2026) 6.2. Asia Pacific Urological Cancer Market, by Treatment Type (2020-2026) 6.2. Asia Pacific Urological Cancer Market, by End-Users (2020-2026) 6.2. Asia Pacific Urological Cancer Market, by Country (2020-2026) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Urological Cancer Market (2020-2026) 7.1 Middle East and Africa Urological Cancer Market, by Cancer Type (2020-2026) 7.2. Middle East and Africa Urological Cancer Market, by Treatment Type (2020-2026) 7.2. Middle East and Africa Urological Cancer Market, by End-Users (2020-2026) 7.4. Middle East and Africa Urological Cancer Market, by Country (2020-2026) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Urological Cancer Market (2020-2026) 8.1. Latin America Urological Cancer Market, by Cancer Type (2020-2026) 8.2. Latin America Urological Cancer Market, by Treatment Type (2020-2026) 8.2. Latin America Urological Cancer Market, by End-Users (2020-2026) 8.4 Latin America Urological Cancer Market, by Country (2020-2026) • Brazil • Argentina • Rest Of Latin America 9. European Urological Cancer Market (2020-2026) 9.1. European Urological Cancer Market, by Cancer Type (2020-2026) 9.2. European Urological Cancer Market, by Treatment Type (2020-2026) 9.3. European Urological Cancer Market, by End-Users (2020-2026) 9.4. European Urological Cancer Market, by Country (2020-2026) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1. Pfizer Inc. 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Novartis International AG 10.3. Johnson & Johnson Private Limited 10.4. Astellas Pharma Inc 10.5. AstraZeneca Plc. 10.6. GlaxoSmithKline plc 10.7. Sanofi S.A. 10.8. Celgene Corporation 10.9. Eli Lilly and Company 10.10. Bristol-Myers Squibb Company 10.11. F. Hoffmann-La Roche AG. 10.12. Kyowa Hakko Kirin Co., Ltd. 10.13. Boehringer Ingelheim GmbH 10.14. Ferring Pharmaceuticals 10.15. Dendreon Corporation 10.16. Abbott Laboratories 10.17. Roche Healthcare 10.18. Indevus Pharmaceuticals Inc 10.19. Ipsen

About This Report

Report ID85866
Category Healthcare
Published DateMarch 2021
Updated DateOct 2021
Contact Us